Akademik Veri Yönetim Sistemi
SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, cilt.42, sa.3, 2025 (SCI-Expanded, Scopus)
Background and aim: To determine the clinical and radiological indicators of disease progression in a newly diagnosed patient with sarcoidosis. Methods: Data of patients diagnosed with sarcoidosis in our department between January 2014 and June 2022 were analyzed. The patients were divided into two groups: progression and non-progression. The groups were compared according to symptoms at the time of diagnosis, comorbidities, foci of extrapulmonary involvement, shape, size, density, localization of mediastinal lymph nodes, parenchymal findings, disease stage, and whether treatment was received at the beginning. Results: This study included 292 sarcoidosis patients. Forty-six patients progressed, and 46 (15.8%) progressed. It was observed that stage II patients progressed more than stage I patients (p<0,001). The mean time to progression was 38.05 +/- 30.45 months in stage I and 28 +/- 58 months in stage II. The progression rate was higher in patients with right upper paratracheal, subaortic-para-aortic, and subcarinal LAP (p=0.010, p=0.012, and p=0.020, respectively). A higher number of stations with LAP was associated with disease progression (p=0.017). The presence of parenchymal nodules (29/64.4%) and number of lobes with nodules were also associated with disease progression (p=0.027 and 0.022, respectively). The progression rate was 76.1% in the patients with treatment indications at the time of diagnosis (p<0.001).Conclusions: Disease stage is a prognostically important factor in the course of sarcoidosis, which was supported by the results of our study. Accordingly, it is important to closely follow up patients with high-stage sarcoidosis and identify patients with timely treatment indications.